BiotechTube
Genomic Expression

Genomic Expression

Copenhagen, Denmark· Est.
genomicexpression.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Genomic Expression is a Copenhagen-based biotech leveraging its OneRNA® platform to transform cancer care through comprehensive RNA analysis. The company's initial commercial application is in breast and ovarian cancer, where its test identifies multiple treatment options, including approved drug repurposing, for individual patients. Led by an experienced team, the company is transitioning from an angel-funded, grant-supported startup to raising a Series A to scale its diagnostic offerings and expand its pipeline into novel RNA therapeutic development. Its vision is to make AI-driven, RNA-based precision medicine a standard part of clinical care.

Oncology

Technology Platform

OneRNA® platform performing whole-transcriptome (~20,000 mRNA) sequencing analysis for disease detection, drug repurposing, and novel RNA therapeutic discovery.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing precision oncology market demands comprehensive profiling beyond DNA, creating a significant opportunity for RNA-based diagnostics.
The platform's application in pharmaceutical R&D for biomarker and companion diagnostic development offers a high-value partnership and revenue channel.
The explosive growth of the RNA therapeutics field provides a long-term pathway to transform from a diagnostic to a therapeutic company.

Risk Factors

Commercialization risk is high, requiring successful market penetration against established diagnostic competitors and integration into clinical practice.
The company is dependent on raising its Series A financing to execute its launch plans and scale.
The scientific premise, while promising, requires continued robust clinical validation to achieve widespread adoption and reimbursement.

Competitive Landscape

Genomic Expression competes in the molecular diagnostics space with large, established players like Foundation Medicine (owned by Roche) and Guardant Health, which offer comprehensive genomic profiling (CGP) tests. Its differentiation is the exclusive focus on whole-transcriptome RNA analysis versus DNA or targeted RNA panels. In the RNA analysis niche, it faces competition from companies like NanoString and emerging transcriptomics startups. Its therapeutic discovery ambition would later pit it against a wide array of RNA-focused biotechs.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →